News

 

 

SeaDragon Investor Update March 2014

SeaDragon, Australasia’s largest refiner and blender of high-quality, internationally certified concentrated fish oils and fractions, including Omega-3 oils, today releases its investor update. The update includes:

 

Read more about SeaDragon Investor Update March 2014

Nexvet unveils clinical data supporting its novel pain treatment for dogs

04 December, 2013. Link here.

Read more about Nexvet unveils clinical data supporting its novel pain treatment for dogs

Avita Medical December 2013 Half Year Report

ASX Announcement (link here).

Read more about Avita Medical December 2013 Half Year Report

SeaDragon signs significant raw material supply contract

Australasia’s largest fish-oil refiner SeaDragon (NZX: SEA) announces a new raw material supply agreement has been signed that will underpin its Nelson-based squalene manufacturing operations, and enable the business to seek new market opportunities in the pharmaceutical and cosmetic sectors.

Read more about SeaDragon signs significant raw material supply contract

AmpliPhi to Present at Upcoming Healthcare Conferences

AmpliPhi BioSciences Corporation (OTCBB: APHB), the leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, announced that President and CEO, Philip Young will be presenting at the Cowen and Company 34^th Annual Healthcare Conference at the Boston Marriott Copley Place Hotel in Boston at 2:50 pm EST (11:50 am PST) on Monday, March 3, 2014.

Read more about AmpliPhi to Present at Upcoming Healthcare Conferences

Bioxyne Ltd completes sale of HI-164OV program to Mariposa Health Ltd

Link to press release here.

Read more about Bioxyne Ltd completes sale of HI-164OV program to Mariposa Health Ltd

ASX BIOTECH STOCKS SURGE 54% IN 2013

7 January 2014: Analysis from leading healthcare fund manager BioScience Managers has highlighted the outstanding year for biotech stocks on the ASX in 2013 with an average gain of 53.6%* across...

Read more about ASX BIOTECH STOCKS SURGE 54% IN 2013

AmpliPhi Biosciences Announces $18 Million Private Placement

AmpliPhi BioSciences Corporation (OTCBB: APHB), the global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, announced today that it has entered into a definitive stock purchase agreement to raise approximately $18 million in a private placement financing. 

Read more about AmpliPhi Biosciences Announces $18 Million Private Placement

Alchemia expands executive leadership team, appointing Thomas Liquard as Chief Operating Officer

ASX announcement here.

Read more about Alchemia expands executive leadership team, appointing Thomas Liquard as Chief Operating Officer

Biota Initiates Dosing in Phase 2 IGLOO Trial of LANI in the Northern Hemisphere

Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the “Company”) today announced that it has commenced dosing patients in the Northern Hemisphere portion of its ongoing Phase 2, randomized, double blind, placebo controlled, parallel arm clinical trial of laninamivir octanoate (LANI). 

Read more about Biota Initiates Dosing in Phase 2 IGLOO Trial of LANI in the Northern Hemisphere

1 ... 19 20 21 22 23 ... 25